GlassScriptPhysician profile
Alexandra Bowles
NPI 1073071478
$5,861.84
in general payments reported to CMS, 2019-2025
24 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 95% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,180 · 2022: $728 · 2023: $483 · 2024: $1,764 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,765 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,764.94 |
| Education | $188.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,224.80 | 2021-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $818.94 | 2021-2025 | |
| Incyte Corporation | $386.30 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $355.05 | 2021-2025 | |
| Amgen INC. | $268.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $233.82 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $220.18 | 2022-2025 | Dysport |
| Lilly USA, LLC | $183.98 | 2022-2024 | Olumiant, Taltz |
| Janssen Biotech, INC. | $178.38 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $124.52 | 2021 | |
| Genentech USA, INC. | $124.20 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $123.16 | 2022-2025 | Libtayo |
| Pfizer INC. | $113.45 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $104.19 | 2023-2025 | Zoryve |
| Ucb, INC. | $102.96 | 2024-2025 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $41.50 | 2023-2025 | Anzupgo, Adbry |
| Dermavant Sciences, INC. | $39.84 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $37.51 | 2023-2024 | Ycanth |
| Almirall LLC | $36.85 | 2024-2025 | Klisyri |
| Boston Scientific Corporation | $34.67 | 2025 | Ams 700 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.28 | 2023 | Siliq |
| Organon LLC | $22.46 | 2025 | Vtama |
| Organogenesis INC. | $16.08 | 2025 | Novachor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.